Tuesday 7-8-2014 Pfizer Inc (PFE) $PFE opened at 3
Post# of 190
Posted On: 07/08/2014 4:29:47 PM
Tuesday 7-8-2014 Pfizer Inc (PFE) $PFE opened at 30.48 hitting the high price of 30.49 and a day low of 30.02 with a total volume of 21,683,953. PFE had a previous close of 30.49 and has been seeing an average volume of 21,972,580.
Overall Average: 40% Buy
Recent stock forum discussions about PFE http://investorshangout.com/search?q=PFE&...mp;yt0=Go!
The Internet Is Brutally Efficient and Totally Agnostic
at The Street - 2 hrs 19 mins ago
Investors should remove their emotion when thinking of the Internet. (full story)
Most active New York Stock Exchange-traded stocks
AP - 2 hrs 47 mins ago
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at 1 p.m.: (full story)
Midday Glance: Pharmaceuticals companies
AP - 2 hrs 47 mins ago
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.: (full story)
Global Contraceptives Market 2014-2018 with Actavis, Bayer AG, J&J's, Janssen Pharma, Merck & Co., Pfizer, & Teva Pharmaceutical Leading the Way
M2 - Tue Jul 08, 10:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d964b9/global) has announced the addition of the "Global Contraceptives Market 2014-2018" report to their offering. The global contraceptives market is set to grow at a CAGR of 5.90 percent over the period 2013-2018. The Global Contraceptives market is driven by several factors, of which the growing prevalence of unplanned pregnancies is one of the major drivers. In order to control the 41 percent of unplanned pregnancies out of 208.2 million pregnancies globally, there has been an increase in the number of initiatives by governments and NGOs. Furthermore, the report states that one of the major challenges is the introduction of low-cost generic contraceptives. Recently, pharmaceutical companies have introduced new products into their portfolios or diversified their contraceptive drugs and devices. This trend has been primarily supported by several prominent deals or partnerships to develop or introduce new products with better efficacy and safety profiles. These strategic decisions will help companies to generate revenue and acquire a significant share of the Global Contraceptives market. Some of the major acquisitions in this space include Conceptus Inc. by Bayer, Warner Chilcott plc by Actavis, Uteron Pharma SA by Watson Pharmaceuticals Inc., and Barr Pharmaceuticals Inc. by Teva Pharmaceutical Industries. Some of the other prominent deals include Bayer and USAID partnering to make Microgynon, an oral contraceptive and Starpharma Holdings licensing agreement with Okamoto Industries Inc. for the VivaGel-coated condom. The global contraceptives market can be segmented broadly into two divisions: Drugs and Devices. This report covers the present scenario and the growth prospects of the Global Contraceptives market for the period 2013-2018. To calculate the market size, the report considers revenue generated from the sales of various products used for contraception which include: - Drugs (Oral Contraceptive Pills, Injectable Contraceptives, Topical Contraceptives) - Devices (Male & Female condoms, Diaphragms, IUDs, Vaginal Rings, Female Sponges and Subdermal Contraceptive Implants) Key Vendors: - Actavis plc - Bayer AG - Johnson & Johnson's Janssen Pharmaceuticals, Inc. - Merck & Co. - Pfizer, Inc. - Teva Pharmaceutical Industries, Ltd Other Prominent Vendors: - Adamis Pharmaceuticals Corp. - Agile Therapeutics, Inc. - ANI Pharmaceuticals, Inc. - Ansell Ltd. - Apothecus Pharmaceutical Corp. - Blairex Laboratories Inc. - Church & Dwight, Co. Inc. - Caldwell Consumer Health, LLC. - Ferring International Center S.A - Fuji Latex Co., Ltd. - HLL Lifecare Limited - Mayer Laboratories - Medicines 360 - Karex Berhad - Lipocine Inc. - Lupin Pharmaceuticals, Inc. - Mylan Laboratories Inc. - Okamoto Industries, Inc. - Pantarhei Bioscience B.V. - Paul Hartmann AG - Reckitt Benckiser Group Plc - The Female Health Company For more information visit http://www.researchandmarkets.com/research/d964b9/global (full story)
Cognitive Impairment Associated With Schizophrenia (CIAS) Clinical Trials Review, H1, 2014
M2 - Tue Jul 08, 10:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/85qd7j/cognitive) has announced the addition of the "Cognitive Impairment Associated With Schizophrenia (CIAS) Global Clinical Trials Review, H1, 2014" report to their offering. Cognitive Impairment Associated With Schizophrenia (CIAS) Global Clinical Trials Review, H1, 2014" provides data on the Cognitive Impairment Associated With Schizophrenia (CIAS) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cognitive Impairment Associated With Schizophrenia (CIAS). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Cognitive Impairment Associated With Schizophrenia (CIAS). Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies - Pfizer Inc. - Novartis AG - Merck & Co., Inc. - AbbVie Inc. - Takeda Pharmaceutical Company Limited - Saniona AB - Johnson & Johnson - GlaxoSmithKline plc - VA Greater Los Angeles Healthcare Center - Hamamatsu University School of Medicine - Bronx Veterans Medical Research Foundation - Mashhad University of Medical Sciences - St. Marianna University School of Medicine - Yale University - Indiana University - Central South University - University of Southern Denmark - Northwestern University For more information visit http://www.researchandmarkets.com/research/85qd7j/cognitive (full story)
Early Glance: Pharmaceuticals companies
AP - Tue Jul 08, 9:31AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are down at 10 a.m.: (full story)
Pfizer (PFE) Approaches New Downside Target of $30.25
Comtex SmarTrend(R) - Tue Jul 08, 9:01AM CDT
Shares of Pfizer (NYSE
FE) opened today below their pivot of $30.50 and have already reached the first level of support at $30.37. Investors may be interested in a cross of the next downside pivot targets of $30.25 and $30.00. (full story)
Global Fibromyalgia Clinical Trials Review, H1, 2014
M2 - Tue Jul 08, 8:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/phv6sx/fibromyalgia) has announced the addition of the "Fibromyalgia Global Clinical Trials Review, H1, 2014" report to their offering. Fibromyalgia Global Clinical Trials Review, H1, 2014" provides data on the Fibromyalgia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Fibromyalgia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Fibromyalgia. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies - Pfizer Inc. - Forest Laboratories, Inc. - Eli Lilly and Company - Tonix Pharmaceuticals Holding Corp. - Jazz Pharmaceuticals plc - UCB S.A. - Laboratoires Pierre Fabre SA - Rose Pharmed Biotechnology Co. - GlaxoSmithKline plc - Boehringer Ingelheim GmbH - The University of Granada - National Center for Complementary and Alternative Medicine - National Institute of Arthritis and Musculoskeletal and Skin Diseases - Federal University of Sao Paulo - University of Michigan - Stanford University - Duke University - The Tel Aviv Sourasky Medical Center - University of Gothenburg - U.S. Department of Veterans Affairs For more information visit http://www.researchandmarkets.com/research/ph...bromyalgia (full story)
Here's Why Pfizer Should Buy GlaxoSmithKline
Bob Ciura, The Motley Fool - Motley Fool - Tue Jul 08, 8:00AM CDT
In the aftermath of pharmaceutical giant Pfizer failing in its repeated attempts to acquire European drug maker AstraZeneca , investors may be wondering what's next. After all, Pfizer's enormous offer and seeming willingness to pay quite a... (full story)
Jazz, Novo Among Medicals Showing Healthy Action
at Investor's Business Daily - Mon Jul 07, 5:18PM CDT
Drugmakers and clinical research providers that aim to boost people's well-being worldwide are displaying healthy stock price performance themselves. Ethical drugmakers topped the 197 industry groups tracked by IBD in Monday's issue, just like they... (full story)
The Revolt Against Big Pharma's Astronomical Prices
Cheryl Swanson, The Motley Fool - Motley Fool - Mon Jul 07, 4:01PM CDT
Don't be caught off-guard. Drugmakers are facing a new mandate -- cut prices or be banned. Here's what's afoot. Health plans are increasingly refusing to cover certain drugs unless companies -- including Pfizer and GlaxoSmithKline -- charge... (full story)
Is Bristol-Myers Squibb Co. Destined for Greatness?
Alex Planes, The Motley Fool - Motley Fool - Mon Jul 07, 1:01PM CDT
Investors love stocks that consistently beat the Street without getting ahead of their fundamentals and risking a meltdown. The best stocks offer sustainable market-beating gains, with robust and improving financial metrics that support strong price... (full story)
M&A Activity Hits 7-Year Peak: Next 3 Takeover Targets - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 11:29AM CDT
Global mergers and acquisitions (M&A) activity has heated up considerably in 2014. (full story)
Caterpillar, Intel Have Led the Dow 30 Higher as Earnings Begin
at The Street - Mon Jul 07, 8:51AM CDT
The Dow Industrial Average set a record intraday high above 17,000 on July 3, but 10 of the Dow 30 are down year to date. (full story)
Technical Pulse on Pharma Stocks -- Research on Pfizer, Hospira, Endo Intl., and Nektar Therapeutics
PR Newswire - Mon Jul 07, 6:30AM CDT
The US markets on Thursday, July 3, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 17,068.26, up 0.54% and the NASDAQ Composite closed at 4,485.93, up 0.63%. The S&P 500 finished the session 0.55% higher at 1,985.44. During the trading session, nine out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 721.38, up 0.41%, with the index gaining 7.38% in the previous three months. Investor-Edge has initiated coverage on the following equities: Pfizer Inc. (NYSE: PFE), Hospira Inc. (NYSE: HSP), Endo International PLC (NASDAQ: ENDP) and Nektar Therapeutics (NASDAQ: NKTR). Free technical research on PFE, HSP, ENDP and NKTR can be downloaded upon signing up at: (full story)
Kosher Certifications, Biologic License Applications, Positive Study Results, Development Programs, and Product Acquisitions - Analyst Notes on Pfizer, Novartis, Sanofi, Zogenix and Impax
PR Newswire - Mon Jul 07, 5:40AM CDT
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Novartis AG (NYSE: NVS), Sanofi (NYSE: SNY), Zogenix, Inc. (NASDAQ: ZGNX) and Impax Laboratories Inc. (NASDAQ: IPXL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4487-100free. (full story)
Global Hypercholesterolemia Market 2014-2018 with AbbVie, Astrazeneca, Merck & Co. & Pfizer Dominating
M2 - Mon Jul 07, 4:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h3hp9b/global) has announced the addition of the "Global Hypercholesterolemia Market 2014-2018" report to their offering. The Global Hypercholesterolemia market will grow at a CAGR of 3.81% to 2018 This report covers the present scenario and the growth prospects of the Global Hypercholesterolemia market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various hypercholesterolemia management drugs that are available in the market which includes statins and other serum lipid lowering drugs. The report also presents the vendor landscape and a corresponding detailed analysis of the top five vendors in the Global Hypercholesterolemia market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market. The Hypercholesterolemia market is associated with fierce competition among the market vendors for innovator drugs and generic manufacturers. The existing competition is expected to rise in the forecast period owing to the launch of generic versions for drugs that are set to lose their patent protection in the near-term. For instance, the 2013 fourth quarter sales for Crestor declined in Canada and Australia owing to the loss of exclusivity in these territories. Further, the drug is expected to face an additional decrease in sales as the US patent for the drug candidate is set to expire in 2016, while in the EU and Japan the patent will expire in 2017. In November 2011, Lipitor lost its exclusivity in the US market. Following the entry of its generic versions in May 2012, the US sales of Lipitor decreased by 81 percent in 2012 as compared to the 2011 US sales. According to the report, one of the main drivers in the market is the increasing risk of cardiovascular diseases. Hypercholesterolemia is one of the underlying causes for CVDs. WHO reported that in men aged 40 years, a 10 percent decrease in serum cholesterol levels is associated with a 50 percent reduction in heart disease within 5 years. Hence, risk management for CVDs also involves the reduction of hypercholesterolemia. Key Vendors - AbbVie Inc. - Astrazeneca PLC - Merck & Co., Inc. - Pfizer Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Clinical Pipeline Portfolio - Market Segmentation by Type of Disease - Market Segmentation by MOA - Global Statins Market - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape For more information visit http://www.researchandmarkets.com/research/h3hp9b/global (full story)
Despite Being an Economic Superpower, America Simply Can't Compete With This
Sean Williams, The Motley Fool - Motley Fool - Sun Jul 06, 8:22AM CDT
For all intents and purposes, and not speaking solely from the heart with this being July Fourth weekend and all, America is the truly the world's greatest superpower. Source: Christopher Connell , Flickr. Statistically speaking, the U.S.... (full story)
Would You Support U.S. Companies Making This "Un-American" Move?
Sean Williams, The Motley Fool - Motley Fool - Fri Jul 04, 7:29AM CDT
Following the deepest recession the U.S. economy has witnessed in seven decades, the bull market that has followed has been equally monumental with the broad-based S&P 500 up practically 200% since its March 2009 low. Beyond just seeing the... (full story)
Why Have Procter & Gamble and Pfizer Missed the Dow's Run to 17,000?
Dan Caplinger, The Motley Fool - Motley Fool - Thu Jul 03, 5:00PM CDT
On Thursday, the Dow Jones Industrials closed above the 17,000 level for the first time, as a surge in job creation, and an unexpected drop in the unemployment rate, made investors more comfortable about the strength of the economic recovery.... (full story)
Overall Average: 40% Buy
Recent stock forum discussions about PFE http://investorshangout.com/search?q=PFE&...mp;yt0=Go!
The Internet Is Brutally Efficient and Totally Agnostic
at The Street - 2 hrs 19 mins ago
Investors should remove their emotion when thinking of the Internet. (full story)
Most active New York Stock Exchange-traded stocks
AP - 2 hrs 47 mins ago
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at 1 p.m.: (full story)
Midday Glance: Pharmaceuticals companies
AP - 2 hrs 47 mins ago
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.: (full story)
Global Contraceptives Market 2014-2018 with Actavis, Bayer AG, J&J's, Janssen Pharma, Merck & Co., Pfizer, & Teva Pharmaceutical Leading the Way
M2 - Tue Jul 08, 10:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d964b9/global) has announced the addition of the "Global Contraceptives Market 2014-2018" report to their offering. The global contraceptives market is set to grow at a CAGR of 5.90 percent over the period 2013-2018. The Global Contraceptives market is driven by several factors, of which the growing prevalence of unplanned pregnancies is one of the major drivers. In order to control the 41 percent of unplanned pregnancies out of 208.2 million pregnancies globally, there has been an increase in the number of initiatives by governments and NGOs. Furthermore, the report states that one of the major challenges is the introduction of low-cost generic contraceptives. Recently, pharmaceutical companies have introduced new products into their portfolios or diversified their contraceptive drugs and devices. This trend has been primarily supported by several prominent deals or partnerships to develop or introduce new products with better efficacy and safety profiles. These strategic decisions will help companies to generate revenue and acquire a significant share of the Global Contraceptives market. Some of the major acquisitions in this space include Conceptus Inc. by Bayer, Warner Chilcott plc by Actavis, Uteron Pharma SA by Watson Pharmaceuticals Inc., and Barr Pharmaceuticals Inc. by Teva Pharmaceutical Industries. Some of the other prominent deals include Bayer and USAID partnering to make Microgynon, an oral contraceptive and Starpharma Holdings licensing agreement with Okamoto Industries Inc. for the VivaGel-coated condom. The global contraceptives market can be segmented broadly into two divisions: Drugs and Devices. This report covers the present scenario and the growth prospects of the Global Contraceptives market for the period 2013-2018. To calculate the market size, the report considers revenue generated from the sales of various products used for contraception which include: - Drugs (Oral Contraceptive Pills, Injectable Contraceptives, Topical Contraceptives) - Devices (Male & Female condoms, Diaphragms, IUDs, Vaginal Rings, Female Sponges and Subdermal Contraceptive Implants) Key Vendors: - Actavis plc - Bayer AG - Johnson & Johnson's Janssen Pharmaceuticals, Inc. - Merck & Co. - Pfizer, Inc. - Teva Pharmaceutical Industries, Ltd Other Prominent Vendors: - Adamis Pharmaceuticals Corp. - Agile Therapeutics, Inc. - ANI Pharmaceuticals, Inc. - Ansell Ltd. - Apothecus Pharmaceutical Corp. - Blairex Laboratories Inc. - Church & Dwight, Co. Inc. - Caldwell Consumer Health, LLC. - Ferring International Center S.A - Fuji Latex Co., Ltd. - HLL Lifecare Limited - Mayer Laboratories - Medicines 360 - Karex Berhad - Lipocine Inc. - Lupin Pharmaceuticals, Inc. - Mylan Laboratories Inc. - Okamoto Industries, Inc. - Pantarhei Bioscience B.V. - Paul Hartmann AG - Reckitt Benckiser Group Plc - The Female Health Company For more information visit http://www.researchandmarkets.com/research/d964b9/global (full story)
Cognitive Impairment Associated With Schizophrenia (CIAS) Clinical Trials Review, H1, 2014
M2 - Tue Jul 08, 10:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/85qd7j/cognitive) has announced the addition of the "Cognitive Impairment Associated With Schizophrenia (CIAS) Global Clinical Trials Review, H1, 2014" report to their offering. Cognitive Impairment Associated With Schizophrenia (CIAS) Global Clinical Trials Review, H1, 2014" provides data on the Cognitive Impairment Associated With Schizophrenia (CIAS) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cognitive Impairment Associated With Schizophrenia (CIAS). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Cognitive Impairment Associated With Schizophrenia (CIAS). Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies - Pfizer Inc. - Novartis AG - Merck & Co., Inc. - AbbVie Inc. - Takeda Pharmaceutical Company Limited - Saniona AB - Johnson & Johnson - GlaxoSmithKline plc - VA Greater Los Angeles Healthcare Center - Hamamatsu University School of Medicine - Bronx Veterans Medical Research Foundation - Mashhad University of Medical Sciences - St. Marianna University School of Medicine - Yale University - Indiana University - Central South University - University of Southern Denmark - Northwestern University For more information visit http://www.researchandmarkets.com/research/85qd7j/cognitive (full story)
Early Glance: Pharmaceuticals companies
AP - Tue Jul 08, 9:31AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are down at 10 a.m.: (full story)
Pfizer (PFE) Approaches New Downside Target of $30.25
Comtex SmarTrend(R) - Tue Jul 08, 9:01AM CDT
Shares of Pfizer (NYSE
FE) opened today below their pivot of $30.50 and have already reached the first level of support at $30.37. Investors may be interested in a cross of the next downside pivot targets of $30.25 and $30.00. (full story) Global Fibromyalgia Clinical Trials Review, H1, 2014
M2 - Tue Jul 08, 8:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/phv6sx/fibromyalgia) has announced the addition of the "Fibromyalgia Global Clinical Trials Review, H1, 2014" report to their offering. Fibromyalgia Global Clinical Trials Review, H1, 2014" provides data on the Fibromyalgia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Fibromyalgia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Fibromyalgia. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies - Pfizer Inc. - Forest Laboratories, Inc. - Eli Lilly and Company - Tonix Pharmaceuticals Holding Corp. - Jazz Pharmaceuticals plc - UCB S.A. - Laboratoires Pierre Fabre SA - Rose Pharmed Biotechnology Co. - GlaxoSmithKline plc - Boehringer Ingelheim GmbH - The University of Granada - National Center for Complementary and Alternative Medicine - National Institute of Arthritis and Musculoskeletal and Skin Diseases - Federal University of Sao Paulo - University of Michigan - Stanford University - Duke University - The Tel Aviv Sourasky Medical Center - University of Gothenburg - U.S. Department of Veterans Affairs For more information visit http://www.researchandmarkets.com/research/ph...bromyalgia (full story)
Here's Why Pfizer Should Buy GlaxoSmithKline
Bob Ciura, The Motley Fool - Motley Fool - Tue Jul 08, 8:00AM CDT
In the aftermath of pharmaceutical giant Pfizer failing in its repeated attempts to acquire European drug maker AstraZeneca , investors may be wondering what's next. After all, Pfizer's enormous offer and seeming willingness to pay quite a... (full story)
Jazz, Novo Among Medicals Showing Healthy Action
at Investor's Business Daily - Mon Jul 07, 5:18PM CDT
Drugmakers and clinical research providers that aim to boost people's well-being worldwide are displaying healthy stock price performance themselves. Ethical drugmakers topped the 197 industry groups tracked by IBD in Monday's issue, just like they... (full story)
The Revolt Against Big Pharma's Astronomical Prices
Cheryl Swanson, The Motley Fool - Motley Fool - Mon Jul 07, 4:01PM CDT
Don't be caught off-guard. Drugmakers are facing a new mandate -- cut prices or be banned. Here's what's afoot. Health plans are increasingly refusing to cover certain drugs unless companies -- including Pfizer and GlaxoSmithKline -- charge... (full story)
Is Bristol-Myers Squibb Co. Destined for Greatness?
Alex Planes, The Motley Fool - Motley Fool - Mon Jul 07, 1:01PM CDT
Investors love stocks that consistently beat the Street without getting ahead of their fundamentals and risking a meltdown. The best stocks offer sustainable market-beating gains, with robust and improving financial metrics that support strong price... (full story)
M&A Activity Hits 7-Year Peak: Next 3 Takeover Targets - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 11:29AM CDT
Global mergers and acquisitions (M&A) activity has heated up considerably in 2014. (full story)
Caterpillar, Intel Have Led the Dow 30 Higher as Earnings Begin
at The Street - Mon Jul 07, 8:51AM CDT
The Dow Industrial Average set a record intraday high above 17,000 on July 3, but 10 of the Dow 30 are down year to date. (full story)
Technical Pulse on Pharma Stocks -- Research on Pfizer, Hospira, Endo Intl., and Nektar Therapeutics
PR Newswire - Mon Jul 07, 6:30AM CDT
The US markets on Thursday, July 3, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 17,068.26, up 0.54% and the NASDAQ Composite closed at 4,485.93, up 0.63%. The S&P 500 finished the session 0.55% higher at 1,985.44. During the trading session, nine out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 721.38, up 0.41%, with the index gaining 7.38% in the previous three months. Investor-Edge has initiated coverage on the following equities: Pfizer Inc. (NYSE: PFE), Hospira Inc. (NYSE: HSP), Endo International PLC (NASDAQ: ENDP) and Nektar Therapeutics (NASDAQ: NKTR). Free technical research on PFE, HSP, ENDP and NKTR can be downloaded upon signing up at: (full story)
Kosher Certifications, Biologic License Applications, Positive Study Results, Development Programs, and Product Acquisitions - Analyst Notes on Pfizer, Novartis, Sanofi, Zogenix and Impax
PR Newswire - Mon Jul 07, 5:40AM CDT
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Novartis AG (NYSE: NVS), Sanofi (NYSE: SNY), Zogenix, Inc. (NASDAQ: ZGNX) and Impax Laboratories Inc. (NASDAQ: IPXL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4487-100free. (full story)
Global Hypercholesterolemia Market 2014-2018 with AbbVie, Astrazeneca, Merck & Co. & Pfizer Dominating
M2 - Mon Jul 07, 4:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h3hp9b/global) has announced the addition of the "Global Hypercholesterolemia Market 2014-2018" report to their offering. The Global Hypercholesterolemia market will grow at a CAGR of 3.81% to 2018 This report covers the present scenario and the growth prospects of the Global Hypercholesterolemia market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various hypercholesterolemia management drugs that are available in the market which includes statins and other serum lipid lowering drugs. The report also presents the vendor landscape and a corresponding detailed analysis of the top five vendors in the Global Hypercholesterolemia market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market. The Hypercholesterolemia market is associated with fierce competition among the market vendors for innovator drugs and generic manufacturers. The existing competition is expected to rise in the forecast period owing to the launch of generic versions for drugs that are set to lose their patent protection in the near-term. For instance, the 2013 fourth quarter sales for Crestor declined in Canada and Australia owing to the loss of exclusivity in these territories. Further, the drug is expected to face an additional decrease in sales as the US patent for the drug candidate is set to expire in 2016, while in the EU and Japan the patent will expire in 2017. In November 2011, Lipitor lost its exclusivity in the US market. Following the entry of its generic versions in May 2012, the US sales of Lipitor decreased by 81 percent in 2012 as compared to the 2011 US sales. According to the report, one of the main drivers in the market is the increasing risk of cardiovascular diseases. Hypercholesterolemia is one of the underlying causes for CVDs. WHO reported that in men aged 40 years, a 10 percent decrease in serum cholesterol levels is associated with a 50 percent reduction in heart disease within 5 years. Hence, risk management for CVDs also involves the reduction of hypercholesterolemia. Key Vendors - AbbVie Inc. - Astrazeneca PLC - Merck & Co., Inc. - Pfizer Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Clinical Pipeline Portfolio - Market Segmentation by Type of Disease - Market Segmentation by MOA - Global Statins Market - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape For more information visit http://www.researchandmarkets.com/research/h3hp9b/global (full story)
Despite Being an Economic Superpower, America Simply Can't Compete With This
Sean Williams, The Motley Fool - Motley Fool - Sun Jul 06, 8:22AM CDT
For all intents and purposes, and not speaking solely from the heart with this being July Fourth weekend and all, America is the truly the world's greatest superpower. Source: Christopher Connell , Flickr. Statistically speaking, the U.S.... (full story)
Would You Support U.S. Companies Making This "Un-American" Move?
Sean Williams, The Motley Fool - Motley Fool - Fri Jul 04, 7:29AM CDT
Following the deepest recession the U.S. economy has witnessed in seven decades, the bull market that has followed has been equally monumental with the broad-based S&P 500 up practically 200% since its March 2009 low. Beyond just seeing the... (full story)
Why Have Procter & Gamble and Pfizer Missed the Dow's Run to 17,000?
Dan Caplinger, The Motley Fool - Motley Fool - Thu Jul 03, 5:00PM CDT
On Thursday, the Dow Jones Industrials closed above the 17,000 level for the first time, as a surge in job creation, and an unexpected drop in the unemployment rate, made investors more comfortable about the strength of the economic recovery.... (full story)
(0)
(0)Pfizer Inc. (PFE) Stock Research Links
Scroll down for more posts ▼